# Multi-center, Open-label, Single-ascending Dose Study of Safety and Tolerability of TN-201 in Adults With Symptomatic MYBPC3 Mutation-associated HCM

> **NCT05836259** · PHASE1,PHASE2 · RECRUITING · sponsor: **Tenaya Therapeutics** · enrollment: 30 (estimated)

## Conditions studied

- Hypertrophic Cardiomyopathy

## Interventions

- **GENETIC:** TN-201

## Key facts

- **NCT ID:** NCT05836259
- **Lead sponsor:** Tenaya Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-08-10
- **Primary completion:** 2027-08
- **Final completion:** 2032-08
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2026-03-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05836259

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05836259, "Multi-center, Open-label, Single-ascending Dose Study of Safety and Tolerability of TN-201 in Adults With Symptomatic MYBPC3 Mutation-associated HCM". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05836259. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*